RxDoctor Payments Data

Meng Lan Cheung Gan

Family · Dallas, TXNPI 1366686362

Payments from drug & device makers

$8,178in general payments, 2019–2025

Across 65 payments — averaging $125.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otter Pharmaceuticals, LLC$3K
  • Livanova USA, Inc.$2K
  • SK Life Science, Inc.$612
  • UCB, Inc.$447
  • Neurelis, Inc.$335
  • Amgen$221
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$1,83222%
  • Travel & lodging$2,68333%
  • Food & beverage$3,66345%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,178 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$51,310
Medicare patients
245
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam179$544,078
EpidiolexCannabidiol (Cbd)89$507,745
XcopriCenobamate276$450,132
KeppraLevetiracetam54$193,017
FinteplaFenfluramine Hcl12$165,431
VimpatLacosamide66$110,883
FycompaPerampanel57$100,967
Lacosamide516$97,961
Lamictal XrLamotrigine38$88,664
NayzilamMidazolam57$83,191
LamictalLamotrigine31$72,334
TrileptalOxcarbazepine20$65,236
Keppra XrLevetiracetam24$58,181
AptiomEslicarbazepine Acetate17$57,170
OnfiClobazam25$52,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Fintepla, Vimpat, Nayzilam$447$903,583314 claims
SK Life Science, Inc.Xcopri$612$450,132276 claims
Eisai Inc.Fycompa$12$100,96757 claims
Sunovion Pharmaceuticals Inc.Aptiom$23$57,17017 claims
Neurelis, Inc.Valtoco$335$17,53614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →